Last updated: February 20, 2026
What is NDC 00245-0144?
NDC 00245-0144 refers to a specific pharmaceutical product. It is identified as a branded formulation of carfilzomib, marketed under the brand name Kyprolis. This drug is used for the treatment of multiple myeloma, particularly in relapsed or refractory cases.
Current Market Status
Market Size and Demand
- Global multiple myeloma drug market reached approximately $12 billion in 2022 and is expected to grow at a CAGR of 8.5% through 2027.
- Kyprolis holds around a 15% market share within the proteasome inhibitor segment.
- The drug is primarily prescribed in the US, which accounts for approximately 75% of the market. Europe and Asia-Pacific represent growing but smaller markets.
Competition
Major competitors include:
- Bortezomib (Velcade) from Takeda
- Ixazomib (Ninlaro) from Takeda
- Carfilzomib manufacturers are limited; Kyprolis is the leading proteasome inhibitor in its segment.
Prescribing Trends
- Increasing use in combination therapies (e.g., Kyprolis + dexamethasone + daratumumab).
- Shift toward earlier treatment lines as more clinical data supports efficacy.
Pricing Dynamics
Current Price Points
- Average wholesale price (AWP) in the US per 28-day treatment cycle: approximately $14,400.
- List price for a single 60 mg vial: around $1,200.
- Pricing varies by dosage, provider contracts, and payer negotiations.
Reimbursement Environment
- Kyprolis is reimbursed predominantly via Medicare and private insurers.
- Co-pay assistance programs impact patient out-of-pocket costs.
- Payers increasingly favor cost-effective regimens, impacting Kyprolis's negotiated prices.
Future Price Projections
Factors Influencing Price Trajectory
- Patent Status: Expected expiration for Kyprolis's main patent in 2028, opening opportunities for biosimilars.
- Biosimilar Competition: Entry expected within 2-3 years after patent expiry, potentially reducing prices by 20-40%.
- Market Penetration: Growing adoption in earlier lines of therapy; impacts volume more than price.
- Regulatory Changes: Potential Medicaid and Medicare reimbursement reforms could pressure pricing.
Projected Pricing Trends (2023–2030)
| Year |
Estimated Price Range per 28-day Cycle |
Key Factors |
| 2023 |
$13,800 – $14,400 |
Stable, with minor negotiations |
| 2025 |
$13,200 – $14,000 |
Price pressure from increased competition |
| 2028 |
$10,400 – $12,800 |
Patent expiration, biosimilar entry anticipated |
| 2030 |
$9,600 – $11,200 |
Biosimilar market penetration, generic options grow |
Impact of Biosimilars
- Biosimilar proteasome inhibitors could reduce the price of Kyprolis by as much as 30-50%, depending on market acceptance.
- Biosimilars may initially target second-line or off-label uses, gradually impacting first-line pricing.
Strategic Considerations for Stakeholders
- Pharmaceutical companies should monitor patent timelines and biosimilar development progress.
- Payers will focus on cost containment, pressuring upstream prices.
- Investors should evaluate volume growth potential against upcoming patent expirations.
Key Takeaways
- The current market is dominated by Kyprolis with stable prices around $14,400 per cycle.
- Competition and biosimilar entries are expected to exert downward pressure starting in 2028.
- Future price declines could reach 20-50% post-biosimilar entry.
- Volume growth driven by combination therapies and earlier-line use may offset some price erosion.
- Monitoring patent expiry and biosimilar pipeline developments is critical for accurate valuation.
FAQs
1. When will biosimilars for Kyprolis likely enter the market?
Biosimilars could launch approximately 5 years after patent expiry, around 2028.
2. How much could prices decline with biosimilar competition?
Prices might decrease by 30-50%, depending on market acceptance and regulatory factors.
3. What is the primary driver for Kyprolis's market share growth?
Expansion into earlier treatment lines and increased combination therapy use.
4. How does reimbursement influence pricing strategies?
Payers' negotiations and formulary decisions pressure list prices and reimbursement rates.
5. Are there emerging therapies threatening Kyprolis's market position?
Yes, new proteasome inhibitors and novel treatments are in development, potentially challenging Kyprolis's dominance.
References
[1] MarketWatch. (2022). Multiple myeloma drugs market size and forecast.
[2] IQVIA. (2022). US Oncology Drug Trends Report.
[3] FDA. (2023). Approved drugs and patent expiration data.
[4] EvaluatePharma. (2023). Oncology drug market outlook.
[5] Centers for Medicare & Medicaid Services. (2022). Reimbursement policies and pricing.
